Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fingolimod vs Interferon β-1a in Pediatric Multiple Sclerosis
NCT01892722Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2013
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 25
01
Overview
A Phase 3 trial of fingolimod in multiple sclerosis (MS), sponsored by Novartis. Started Jul 2013; status: active, not recruiting.
02
Drugs
fingolimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT01892722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01892722.